MX2016015567A - Proteinas prohemostaticas para el tratamiento de hemorragias. - Google Patents

Proteinas prohemostaticas para el tratamiento de hemorragias.

Info

Publication number
MX2016015567A
MX2016015567A MX2016015567A MX2016015567A MX2016015567A MX 2016015567 A MX2016015567 A MX 2016015567A MX 2016015567 A MX2016015567 A MX 2016015567A MX 2016015567 A MX2016015567 A MX 2016015567A MX 2016015567 A MX2016015567 A MX 2016015567A
Authority
MX
Mexico
Prior art keywords
bleeding
treatment
proteins
prohemostatic
subject
Prior art date
Application number
MX2016015567A
Other languages
English (en)
Inventor
Verhoef Daniël
H Reitsma Pieter
H A Bos Mettine
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of MX2016015567A publication Critical patent/MX2016015567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a polipéptidos del FXa recombinante que pueden usarse como antídotos para revertir completamente o parcialmente el efecto anticoagulante de un inhibidor de coagulación en un sujeto, preferiblemente un inhibidor directo del factor Xa; se describen aquí proteínas del factor Xa recombinante y un método para revertir total o parcialmente un efecto anticoagulante de un inhibidor de coagulación en un sujeto.
MX2016015567A 2014-05-26 2015-05-26 Proteinas prohemostaticas para el tratamiento de hemorragias. MX2016015567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26
PCT/NL2015/050377 WO2015183085A1 (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Publications (1)

Publication Number Publication Date
MX2016015567A true MX2016015567A (es) 2017-06-29

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015567A MX2016015567A (es) 2014-05-26 2015-05-26 Proteinas prohemostaticas para el tratamiento de hemorragias.
MX2020013410A MX2020013410A (es) 2014-05-26 2016-11-25 Proteinas prohemostaticas para el tratamiento de hemorragias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013410A MX2020013410A (es) 2014-05-26 2016-11-25 Proteinas prohemostaticas para el tratamiento de hemorragias.

Country Status (25)

Country Link
US (4) US10537618B2 (es)
EP (2) EP3744840A1 (es)
JP (3) JP6640198B2 (es)
KR (2) KR102351728B1 (es)
CN (1) CN106536566A (es)
AU (2) AU2015268149B2 (es)
BR (1) BR112016027649A2 (es)
CA (1) CA2949349A1 (es)
DK (1) DK3149163T3 (es)
EA (2) EA202190813A1 (es)
ES (1) ES2813440T3 (es)
HR (1) HRP20201311T1 (es)
HU (1) HUE052098T2 (es)
IL (2) IL249132B (es)
LT (1) LT3149163T (es)
MA (2) MA40042B1 (es)
MX (2) MX2016015567A (es)
NZ (1) NZ727444A (es)
PL (1) PL3149163T3 (es)
PT (1) PT3149163T (es)
RS (1) RS60706B1 (es)
SG (2) SG11201609811TA (es)
SI (1) SI3149163T1 (es)
WO (1) WO2015183085A1 (es)
ZA (1) ZA201608017B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3149163T (lt) 2014-05-26 2020-09-25 Academisch Ziekenhuis Leiden Prohemostatiniai baltymai, skirti kraujavimo gydymui
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
EP0574402B2 (en) 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
AU2008239586B2 (en) * 2007-04-13 2013-09-26 Catalyst Biosciences, Inc. Modified factor VII polypetides and uses thereof
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
JP6363600B2 (ja) * 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
CN104994868A (zh) 2013-01-31 2015-10-21 辉瑞公司 用于抵消因子Xa抑制的组合物和方法
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
LT3149163T (lt) * 2014-05-26 2020-09-25 Academisch Ziekenhuis Leiden Prohemostatiniai baltymai, skirti kraujavimo gydymui

Also Published As

Publication number Publication date
BR112016027649A2 (pt) 2017-08-15
NZ727444A (en) 2021-12-24
EA202190813A1 (ru) 2021-12-31
AU2021203838A1 (en) 2021-07-08
CA2949349A1 (en) 2015-12-03
MX2020013410A (es) 2021-02-26
ZA201608017B (en) 2019-04-24
US20200138916A1 (en) 2020-05-07
EP3744840A1 (en) 2020-12-02
LT3149163T (lt) 2020-09-25
EA201692161A1 (ru) 2017-08-31
JP2020062039A (ja) 2020-04-23
JP6640198B2 (ja) 2020-02-05
CN106536566A (zh) 2017-03-22
AU2015268149A1 (en) 2016-12-08
KR102245264B1 (ko) 2021-04-28
IL277377A (en) 2020-11-30
US11304995B2 (en) 2022-04-19
PT3149163T (pt) 2020-09-03
HUE052098T2 (hu) 2021-04-28
AU2021203838B2 (en) 2023-03-02
US20170157223A1 (en) 2017-06-08
JP2022134139A (ja) 2022-09-14
US20220288172A1 (en) 2022-09-15
EP3149163B1 (en) 2020-06-03
RS60706B1 (sr) 2020-09-30
SG11201609811TA (en) 2016-12-29
US20200138917A1 (en) 2020-05-07
EP3149163A1 (en) 2017-04-05
US10537618B2 (en) 2020-01-21
WO2015183085A1 (en) 2015-12-03
EA037991B1 (ru) 2021-06-21
HRP20201311T1 (hr) 2020-12-11
ES2813440T3 (es) 2021-03-23
IL277377B (en) 2021-10-31
SI3149163T1 (sl) 2020-10-30
KR20170020332A (ko) 2017-02-22
IL249132B (en) 2020-09-30
US11357836B2 (en) 2022-06-14
KR20210054573A (ko) 2021-05-13
MA51688A (fr) 2020-12-02
SG10201906329VA (en) 2019-08-27
IL249132A0 (en) 2017-01-31
DK3149163T3 (da) 2020-08-31
JP2017522900A (ja) 2017-08-17
MA40042B1 (fr) 2020-08-31
KR102351728B1 (ko) 2022-01-14
AU2015268149B2 (en) 2021-03-11
PL3149163T3 (pl) 2020-12-28

Similar Documents

Publication Publication Date Title
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
EA201791775A1 (ru) Цистеиновая протеаза
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
MD4801C1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790380A1 (ru) Ингибиторы mk2 и их применения
LT3197472T (lt) Rekombinantinių baltymų be fenilalanino naudojimas gydant fenilketonuriją
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2020013410A (es) Proteinas prohemostaticas para el tratamiento de hemorragias.
PH12016501608A1 (en) Peptides and methods of use
EA201501176A1 (ru) Замещенные бензоксазолы
MX2018006479A (es) Serinas proteasas recombinantes.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
EA202090225A2 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp